Efficacy and safety analysis of immune checkpoint inhibitors combined with chemotherapy in the treatment of advanced triple-negative breast cancer: an umbrella meta-analysis - Scorecard - MDSpire
Advertisement
Assessment of the Safety and Effectiveness of Combining Immune Checkpoint Inhibitors with Chemotherapy for Advanced Triple-Negative Breast Cancer: A Comprehensive Meta-Analysis
Clinical Scorecard: Assessment of the Safety and Effectiveness of Combining Immune Checkpoint Inhibitors with Chemotherapy for Advanced Triple-Negative Breast Cancer: A Comprehensive Meta-Analysis
At a Glance
Category
Detail
Condition
Triple-Negative Breast Cancer (TNBC)
Key Mechanisms
Immune checkpoint inhibitors (ICIs) block the PD-1/PD-L1 axis, reactivating T-cell responses against tumors.
Target Population
Patients with advanced triple-negative breast cancer.
Care Setting
Oncology clinical practice.
Key Highlights
ICIs combined with chemotherapy significantly improved overall survival (OS) and progression-free survival (PFS).
No significant improvement in objective response rate (ORR) for PD-L1-negative or PD-L1-positive populations.
Combination therapy increased risks of all-grade and grade ≥3 adverse events.
Higher incidence of immune-related adverse events (irAEs) observed.
Future research needed for detailed stratification in treatment.
Guideline-Based Recommendations
Diagnosis
Diagnosis of TNBC should include assessment of ER, PR, and HER2 status.
Management
ICIs plus chemotherapy is recommended as a first-line treatment for advanced TNBC.
Monitoring & Follow-up
Monitor for immune-related adverse events, including thyroid dysfunction, pneumonitis, and skin reactions.
Risks
Increased risk of multisystem immune-related adverse events.
Patient & Prescribing Data
Patients with advanced triple-negative breast cancer.
Combination therapy shows survival benefits but requires careful monitoring for adverse effects.
Clinical Best Practices
Utilize a multidisciplinary approach for managing TNBC treatment.
Incorporate regular assessments for adverse events in patients receiving ICIs.
